Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.
暂无分享,去创建一个
Gerhard Glatting | Sven N Reske | G. Glatting | S. Reske | N. Blumstein | C. Friesen | D. Bunjes | Anja Dankerl | Donald Bunjes | P. Liebisch | Peter Liebisch | Claudia Friesen | Norbert M Blumstein | Darius Kocot | Christiane Wendl | C. Wendl | A. Dankerl | D. Kocot
[1] M. Dimopoulos,et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Morgan,et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. , 2003, The hematology journal : the official journal of the European Haematology Association.
[3] H. Döhner,et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[4] R W Günther,et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. , 2002, AJR. American journal of roentgenology.
[5] H. Goldschmidt,et al. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma , 2003, British journal of haematology.
[6] R. Bataille,et al. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. , 2001, Blood.
[7] D. Comar,et al. Labelling and metabolism of methionine-methyl-11C , 2004, European Journal of Nuclear Medicine.
[8] S. Barrington,et al. Fluoro‐deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma , 2002, British journal of haematology.
[9] B. Maldague,et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey , 1999, British journal of haematology.
[10] M. Reiser,et al. Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.
[11] Gary Caputo,et al. Value of FDG PET in the assessment of patients with multiple myeloma. , 2005, AJR. American journal of roentgenology.
[12] P. Gaulard,et al. Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. , 2003, Radiology.
[13] C. Metz. ROC Methodology in Radiologic Imaging , 1986, Investigative radiology.
[14] H. Schirrmeister,et al. Positron emission tomography (PET) for staging of solitary plasmacytoma. , 2003, Cancer biotherapy & radiopharmaceuticals.
[15] B. Barlogie,et al. Multiple myeloma: clinical review and diagnostic imaging. , 2004, Radiology.
[16] M. Reiser,et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? , 2002, Cancer.
[17] Kenneth C. Anderson,et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.
[18] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[19] M. Coel,et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. , 2005, The Journal of urology.
[20] G. V. von Schulthess,et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.